Dyne Therapeutics, Inc.
DYN
$25.70
-$0.26-1.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.49M | 24.39M | 20.70M | 16.67M | 16.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 181.66M | 125.28M | 116.13M | 113.89M | 115.79M |
| Operating Income | -181.66M | -125.28M | -116.13M | -113.89M | -115.79M |
| Income Before Tax | -178.56M | -120.85M | -111.96M | -108.04M | -110.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -178.56M | -120.85M | -111.96M | -108.04M | -110.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -178.56M | -120.85M | -111.96M | -108.04M | -110.86M |
| EBIT | -181.66M | -125.28M | -116.13M | -113.89M | -115.79M |
| EBITDA | -181.10M | -124.73M | -115.61M | -113.37M | -115.29M |
| EPS Basic | -1.08 | -0.73 | -0.76 | -0.76 | -0.97 |
| Normalized Basic EPS | -0.67 | -0.46 | -0.47 | -0.48 | -0.61 |
| EPS Diluted | -1.08 | -0.73 | -0.76 | -0.76 | -0.97 |
| Normalized Diluted EPS | -0.67 | -0.46 | -0.47 | -0.48 | -0.61 |
| Average Basic Shares Outstanding | 165.45M | 165.04M | 147.62M | 141.81M | 113.87M |
| Average Diluted Shares Outstanding | 165.45M | 165.04M | 147.62M | 141.81M | 113.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |